CN101903026B - 抑制剂在制备用于治疗黄病毒家族病毒感染的药物中的用途 - Google Patents

抑制剂在制备用于治疗黄病毒家族病毒感染的药物中的用途 Download PDF

Info

Publication number
CN101903026B
CN101903026B CN200880116387XA CN200880116387A CN101903026B CN 101903026 B CN101903026 B CN 101903026B CN 200880116387X A CN200880116387X A CN 200880116387XA CN 200880116387 A CN200880116387 A CN 200880116387A CN 101903026 B CN101903026 B CN 101903026B
Authority
CN
China
Prior art keywords
rna
hcv
clemizole
ns4b
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200880116387XA
Other languages
English (en)
Chinese (zh)
Other versions
CN101903026A (zh
Inventor
谢里特·安纳夫
杰弗里·S·格伦
罗伯特·麦克道尔
文锦·杨
哈达斯·多沃里-索博尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of CN101903026A publication Critical patent/CN101903026A/zh
Application granted granted Critical
Publication of CN101903026B publication Critical patent/CN101903026B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/67—Phosphorus compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/186—Hepatitis C; Hepatitis NANB
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN200880116387XA 2007-09-18 2008-09-18 抑制剂在制备用于治疗黄病毒家族病毒感染的药物中的用途 Expired - Fee Related CN101903026B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US97330907P 2007-09-18 2007-09-18
US60/973,309 2007-09-18
US8875908P 2008-08-14 2008-08-14
US61/088,759 2008-08-14
US9253708P 2008-08-28 2008-08-28
US61/092,537 2008-08-28
PCT/US2008/076806 WO2009039248A2 (en) 2007-09-18 2008-09-18 Methods of treating a flaviviridae family viral infection and compositions for treating a flaviviridae family viral infection

Publications (2)

Publication Number Publication Date
CN101903026A CN101903026A (zh) 2010-12-01
CN101903026B true CN101903026B (zh) 2013-05-08

Family

ID=40468758

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880116387XA Expired - Fee Related CN101903026B (zh) 2007-09-18 2008-09-18 抑制剂在制备用于治疗黄病毒家族病毒感染的药物中的用途

Country Status (8)

Country Link
US (3) US9061010B2 (https=)
EP (1) EP2203168B1 (https=)
JP (1) JP5715820B2 (https=)
CN (1) CN101903026B (https=)
AR (1) AR066165A1 (https=)
AU (1) AU2008302295B2 (https=)
TW (1) TW200927102A (https=)
WO (2) WO2009039248A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI881480B (zh) * 2015-06-30 2025-04-21 美商伊格集團國際股份有限公司 克立咪唑(clemizole)化合物於預防及治療肝癌之用途

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8940730B2 (en) 2007-09-18 2015-01-27 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions of treating a Flaviviridae family viral infection
US9149463B2 (en) 2007-09-18 2015-10-06 The Board Of Trustees Of The Leland Standford Junior University Methods and compositions of treating a Flaviviridae family viral infection
JP5715820B2 (ja) * 2007-09-18 2015-05-13 スタンフォード ユニバーシティー フラビウイルス科ファミリーのウイルスへの感染を治療する方法ならびに、フラビウイルス科ファミリーのウイルスへの感染を治療するための組成物
US9101628B2 (en) 2007-09-18 2015-08-11 The Board Of Trustees Of The Leland Stanford Junior University Methods and composition of treating a flaviviridae family viral infection
EP2408448A4 (en) * 2009-03-18 2012-09-19 Univ Leland Stanford Junior METHODS AND COMPOSITIONS FOR TREATING INFECTION WITH A FLAVIVIRIDAE FAMILY VIRUS
EP2408449A4 (en) * 2009-03-18 2012-08-08 Univ Leland Stanford Junior METHOD AND COMPOSITIONS FOR TREATING FLAVIVIRIDAE VIRUS INFECTIONS
US20100284970A1 (en) * 2009-04-09 2010-11-11 Auspex Pharmaceuticals, Inc. Benzimidazole modulators of h1 receptor and/or ns4b protein
WO2010132810A1 (en) * 2009-05-15 2010-11-18 Concert Pharmaceuticals, Inc. Deuterium modified benzimidazoles
RU2407738C1 (ru) * 2009-07-03 2010-12-27 Общество с ограниченной ответственностью "Интеллектуальный Диалог" Противовирусный активный компонент, фармацевтическая композиция, лекарственное средство, способ лечения вирусных заболеваний
CN102666537A (zh) * 2009-10-20 2012-09-12 艾格尔生物制药股份有限公司 治疗黄病毒科病毒感染的氮杂吲唑
US20110165037A1 (en) * 2010-01-07 2011-07-07 Ismagilov Rustem F Interfaces that eliminate non-specific adsorption, and introduce specific interactions
RU2436786C1 (ru) * 2010-07-23 2011-12-20 Александр Васильевич Иващенко Замещенные индолы, противовирусный активный компонент, способ получения и применения
US8765760B2 (en) 2011-01-11 2014-07-01 Sunovion Pharmaceuticals, Inc. [1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases
US9388140B2 (en) 2011-03-31 2016-07-12 Bayer Intellectual Property Gmbh Substituted benzimidazoles
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
DE202012012955U1 (de) 2011-10-21 2014-07-14 Abbvie Inc. Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV
EP2583677A3 (en) 2011-10-21 2013-07-03 Abbvie Inc. Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon.
BR112014013649A2 (pt) 2011-12-06 2020-10-27 The Board Of Trustees Of The Leland Stanford Junior University métodos e agentes para o tratamento de doenças virais e usos dos referidos agentes
BR112014030940B1 (pt) * 2012-06-11 2022-09-06 UCB Biopharma SRL Benzimidazóis que modulam tnf-alfa e composição farmacêutica compreendendo os mesmos
CN103585616B (zh) * 2013-08-14 2015-05-27 南京工业大学 二肽类似物的用途
DK3035926T3 (da) * 2013-08-19 2020-08-31 Univ California Forbindelser og fremgangsmåder til behandling af en epilepsilidelse
WO2015050998A2 (en) 2013-10-01 2015-04-09 The Broad Institute, Inc. Sieve valves, microfluidic circuits, microfluidic devices, kits, and methods for isolating an analyte
HUE059559T2 (hu) 2015-02-25 2022-12-28 Univ California 5HT agonisták az epilepsziás rendellenességek kezelésére
BR112018068956A2 (pt) * 2016-04-01 2019-01-22 Janssen Pharmaceuticals Inc derivados do composto indol substituídos como inibidores da replicação viral da dengue
JP6894923B2 (ja) 2016-04-11 2021-06-30 ジェンフィＧｅｎｆｉｔ 胆汁うっ滞性及び線維性の疾患の処置方法
US10653678B2 (en) 2016-04-11 2020-05-19 Genfit Methods of treatment for cholestatic and fibrotic diseases
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
WO2018129702A1 (zh) * 2017-01-13 2018-07-19 史仅 蚊虫叮咬瘙痒寨卡等病毒预防医疗器具
CN108096562B (zh) * 2017-12-25 2021-05-11 武汉百药联科科技有限公司 20s蛋白酶体抑制剂在制备治疗日本乙型脑炎病毒感染的药物中的用途
WO2019126860A1 (pt) * 2017-12-29 2019-07-04 Instituto Butantan Composição farmacêutica para o tratamento de infecção causada por vírus da família flaviviridae, e, uso da composição
CN108660253B (zh) * 2018-04-17 2022-05-31 广东省妇幼保健院（广东省妇产医院、广东省儿童医院） 一种基于悬浮微珠阵列系统检测虫媒介病毒的探针、引物、检测试剂盒及检测方法
CN109020895B (zh) * 2018-08-07 2020-04-24 枣庄学院 一种金属催化的1-苄胺基取代苯并咪唑的合成方法
MX2021003904A (es) 2018-10-05 2021-10-26 Annapurna Bio Inc Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor apj.
US20200323813A1 (en) * 2019-04-09 2020-10-15 Tremeau Pharmaceuticals, Inc. Treatment of viral hemorrhagic fevers with cox-2 selective non-steroidal anti-inflammatory drugs
MX2022001664A (es) 2019-08-09 2022-07-19 Nutcracker Therapeutics Inc Aparato microfluídico y metodos de uso del mismo.
US20230241037A1 (en) * 2020-03-09 2023-08-03 1Globe Health Institute, Nanjing Cross-linked medication for treatment of coronaviral infection and method of treatment
CN111393372B (zh) * 2020-05-12 2022-08-26 中国药科大学 一种苯并咪唑衍生物及其制备方法和用途
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
JP2024529509A (ja) * 2021-07-30 2024-08-06 エピジェニクス セラピューティクス インコーポレーテッド クレミゾール製剤
CA3251843A1 (en) * 2022-05-20 2023-11-23 The Board Of Trustees Of The Leland Stanford Junior University METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATIC STEATOSE AND VIRAL INFECTIONS
CN119707828B (zh) * 2024-12-18 2025-12-05 江苏天和制药股份有限公司 一种盐酸克立咪唑的合成方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040097438A1 (en) * 1999-12-27 2004-05-20 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
WO2006131737A2 (en) * 2005-06-09 2006-12-14 Biolipox Ab Method and composition for treating inflammatory disorders

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2689853A (en) * 1954-09-21 Certain i
US2684327A (en) 1951-11-02 1954-07-20 United Chromium Inc Bright nickel plating
GB1045534A (en) 1963-02-09 1966-10-12 Schering Ag New 1-benzyl-5,6-dialkoxy benzimidazoles and a process for their manufacture
DE1620449C3 (de) 1964-07-23 1974-02-21 Schering Ag, 1000 Berlin Und 4619 Bergkamen Substituierte Benzimidazole und Verfahren zu ihrer Herstellung
US3428634A (en) 1965-03-13 1969-02-18 Acraf 3-tertiary amino alkoxy-1-hydrocarbon indazoles
DE2436883C2 (de) 1974-07-29 1985-08-22 Schering AG, 1000 Berlin und 4709 Bergkamen Benzimidazol-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US4269835A (en) * 1979-12-13 1981-05-26 Whittle Barry J Nasal composition for relieving nasal distress
PE27997A1 (es) 1994-04-29 1997-09-20 Lilly Co Eli Antagonistas de receptores de taquicininas
US5552426A (en) 1994-04-29 1996-09-03 Eli Lilly And Company Methods for treating a physiological disorder associated with β-amyloid peptide
EP0963371B1 (en) * 1997-02-25 2003-05-02 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase
US6211177B1 (en) 1998-11-24 2001-04-03 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
US6476062B2 (en) 2000-03-30 2002-11-05 Schering Corporation Chemokine receptor antagonists
US6448281B1 (en) * 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
JP2004504356A (ja) 2000-07-20 2004-02-12 メルク　エンド　カムパニー　インコーポレーテッド Ｃ型肝炎ウイルスのプロセシングおよび複製の抑制
DE60204224T2 (de) 2001-03-22 2006-02-02 Ucb S.A. Verwendung bestimmter substituierter pyrrolidone wie z.b. piracetam bei der behandlung von viralen und anderen erkrankungen
AR035543A1 (es) * 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
US7160879B2 (en) 2002-01-10 2007-01-09 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1H-benzoimidazole analogues
TW200509958A (en) 2003-02-14 2005-03-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
BRPI0409227C1 (pt) 2003-04-07 2021-05-25 Axys Pharm Inc composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)
JP2007501189A (ja) 2003-08-01 2007-01-25 ジェネラブス テクノロジーズ，インコーポレイテッド フラビウイルス科に対する二環式イミダゾール誘導体
WO2005032329A2 (en) 2003-08-22 2005-04-14 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for identifying anti-hcv agents
US20050192261A1 (en) 2003-09-15 2005-09-01 Jost-Price Edward R. Methods and reagents for the treatment of immunoinflammatory disorders
WO2005051318A2 (en) * 2003-11-24 2005-06-09 Viropharma Incorporated Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
RU2006134022A (ru) 2004-02-27 2008-04-10 Ф.Хоффманн-Ля Рош Аг (Ch) Производные индазола и содержащие их фармацевтические композиции
BRPI0513811A (pt) 2004-07-27 2008-07-15 Gilead Sciences Inc imidazo [4,5-d] pirimidinas, seus usos e processos de preparação
GB0416728D0 (en) 2004-07-27 2004-09-01 7Tm Pharma As Medicinal use of receptor ligands
WO2006135383A2 (en) 2004-08-04 2006-12-21 Myriad Genetics, Inc. Indazoles
CA2651943C (en) 2006-03-02 2015-06-30 Siga Technologies, Inc. Antiviral drugs for treatment of arenavirus infection
CA2644910C (en) 2006-03-31 2014-01-28 Abbott Laboratories Indazole compounds
CA2646755A1 (en) 2006-03-31 2007-10-11 Astrazeneca Ab Bicyclic benzimidazole compounds and their use as metabotropic glutamate receptor potentiators
WO2008033466A2 (en) * 2006-09-14 2008-03-20 Combinatorx (Singapore) Pre. Ltd. Compositions and methods for treatment of viral diseases
DE102007028521A1 (de) 2007-06-21 2008-12-24 Merck Patent Gmbh Indazolamidderivate
JP5715820B2 (ja) * 2007-09-18 2015-05-13 スタンフォード ユニバーシティー フラビウイルス科ファミリーのウイルスへの感染を治療する方法ならびに、フラビウイルス科ファミリーのウイルスへの感染を治療するための組成物
US9101628B2 (en) 2007-09-18 2015-08-11 The Board Of Trustees Of The Leland Stanford Junior University Methods and composition of treating a flaviviridae family viral infection

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040097438A1 (en) * 1999-12-27 2004-05-20 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
WO2006131737A2 (en) * 2005-06-09 2006-12-14 Biolipox Ab Method and composition for treating inflammatory disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI881480B (zh) * 2015-06-30 2025-04-21 美商伊格集團國際股份有限公司 克立咪唑(clemizole)化合物於預防及治療肝癌之用途

Also Published As

Publication number Publication date
EP2203168A4 (en) 2011-10-26
WO2009039246A3 (en) 2009-06-11
TW200927102A (en) 2009-07-01
WO2009039248A2 (en) 2009-03-26
US20150044169A1 (en) 2015-02-12
AR066165A1 (es) 2009-07-29
EP2203168A2 (en) 2010-07-07
US20100260717A1 (en) 2010-10-14
AU2008302295B2 (en) 2013-11-28
JP5715820B2 (ja) 2015-05-13
US8895598B2 (en) 2014-11-25
EP2203168B1 (en) 2014-07-16
AU2008302295A1 (en) 2009-03-26
US9061010B2 (en) 2015-06-23
US20110052536A1 (en) 2011-03-03
CN101903026A (zh) 2010-12-01
WO2009039246A2 (en) 2009-03-26
JP2010539241A (ja) 2010-12-16
WO2009039248A8 (en) 2009-05-28
WO2009039248A3 (en) 2009-09-24

Similar Documents

Publication Publication Date Title
CN101903026B (zh) 抑制剂在制备用于治疗黄病毒家族病毒感染的药物中的用途
US9101628B2 (en) Methods and composition of treating a flaviviridae family viral infection
CN102448458B (zh) 治疗黄病毒科病毒感染的方法和组合物
US20120232062A1 (en) Azaindazoles to treat flaviviridae virus infection
US20150152064A1 (en) Methods and compositions of treating a flaviviridae family viral infection
CN102448457B (zh) 治疗黄病毒科病毒感染的方法和组合物
US20110217265A1 (en) Screening for Inhibitors of HCV Amphipathic Helix (AH) Function
US10869873B2 (en) Methods and compositions for treating viral diseases
US8940730B2 (en) Methods and compositions of treating a Flaviviridae family viral infection
AU2014201019A1 (en) Methods of treating a flaviviridae family viral infection and compositions for treating a flaviviridae family viral infection

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130508

Termination date: 20160918

CF01 Termination of patent right due to non-payment of annual fee